D. Boral Capital Reiterates “Buy” Rating for Can-Fite BioPharma (NYSE:CANF)

Can-Fite BioPharma (NYSE:CANF)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They presently have a $10.00 price objective on the stock.

CANF has been the topic of several other research reports. StockNews.com downgraded shares of Can-Fite BioPharma from a “hold” rating to a “sell” rating in a research note on Friday, December 13th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th.

Can-Fite BioPharma Stock Performance

Shares of CANF stock opened at $1.63 on Tuesday. The stock has a 50 day moving average price of $1.88 and a 200 day moving average price of $2.36. The firm has a market capitalization of $5.75 million, a P/E ratio of -0.91 and a beta of 1.32. Can-Fite BioPharma has a 52-week low of $1.29 and a 52-week high of $4.69.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC raised its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the quarter. Armistice Capital LLC owned approximately 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.